Grifols (GRFS) Total Liabilities (2010 - 2025)
Grifols (GRFS) reported Total Liabilities of $14.1 billion for Q4 2025, up 3.06% on a YoY basis from $13.7 billion in Q4 2024, and up 3.06% quarter-over-quarter from $13.7 billion in Q4 2024.
Grifols (GRFS) Total Liabilities (2010 - 2025) Analysis & Trends
Grifols has reported Total Liabilities for 16 years, with the latest figure at $14.1 billion in Q4 2025.
- For the quarter ending Q4 2025, Total Liabilities rose 3.06% year-over-year to $14.1 billion; the trailing twelve-month figure through Dec 2025 stood at $14.1 billion (up 3.06% YoY), and the FY2025 full-year result was $14.1 billion, up 13584.86% from the prior year.
- Total Liabilities for Q4 2025 stood at $14.1 billion, up from $13.7 billion in the prior quarter.
- The five-year high for Total Liabilities was $14.5 billion in Q4 2023, with the low at $13.5 billion in Q4 2022.
- Historically, Total Liabilities has averaged $13.9 billion across 5 years, with a median of $13.7 billion in 2024.
- Annual changes were most pronounced in 2021 — Total Liabilities soared 33.65% — and 2024, when it retreated 5.69%.
- Grifols' Total Liabilities stood at $13.6 billion in 2021, then decreased by 0.81% to $13.5 billion in 2022, then gained by 7.25% to $14.5 billion in 2023, then declined by 5.69% to $13.7 billion in 2024, then rose by 3.06% to $14.1 billion in 2025.
- The last three Total Liabilities figures came in at $14.1 billion (Q4 2025), $13.7 billion (Q4 2024), and $14.5 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -61.27 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 85.38 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 119.71 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 143.08 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 82.75 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 66.37 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - | 14.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 13.68 Bn |
| Dec 31, 2023 | 14.50 Bn |
| Dec 31, 2022 | 13.52 Bn |
| Dec 31, 2021 | 13.63 Bn |
| Dec 31, 2020 | 10.20 Bn |
| Sep 30, 2020 | 9.97 Bn |
| Mar 31, 2020 | 9.59 Bn |
| Dec 31, 2019 | 9.63 Bn |
| Sep 30, 2019 | 9.73 Bn |
| Dec 31, 2018 | 8.88 Bn |
| Sep 30, 2018 | 8.88 Bn |
| Jun 30, 2018 | 8.91 Bn |
| Mar 31, 2018 | 10.45 Bn |
| Dec 31, 2017 | 8.58 Bn |
| Jun 30, 2017 | 8.28 Bn |
| Dec 31, 2016 | 6.91 Bn |
| Sep 30, 2016 | 6.74 Bn |
| Jun 30, 2016 | 6.92 Bn |
| Mar 31, 2016 | 100.59 Mn |